Table 1.
Study | Trial registry identifier | Study design | Study location | Study length | Outcomes reported |
---|---|---|---|---|---|
Chu et al. (2016) | NCT02596308 | Phase 2a RCT | China | 3 months | Immunogenicity Safety |
Frey et al. (2017) | NCT01381744 | Phase 1 RCT | US | 13 months | Immunogenicity Safety |
RCT = randomised controlled trial; US = United States.